V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 250007153 | 250012375 | 1.53 | 66.5 | Palliative (P) | 2014-01-05 | 2014-01-05 | RUXOLITINIB | 02 | N | 250031327 | RUXOLITINIB |
| 250007154 | 250012375 | null | null | Curative (C) | 2014-01-21 | 2014-01-22 | Nilotinib | 02 | N | 250031327 | ANAGRELIDE |
| 250007155 | 250005043 | 1.82 | 63 | Palliative (P) | 2015-10-27 | 2015-10-27 | AML16 Azacitidine | 2 | N | 250031340 | RUXOLITINIB |
| 250007156 | 250005043 | null | 64.7 | Disease modification (D) | 2014-03-06 | 2014-03-06 | RUXOLITINIB | N | N | 250031340 | RUXOLITINIB |
| 250007157 | 250005044 | 1.55 | 0 | Palliative (P) | 2016-09-20 | 2016-10-11 | Trial Unspecified | 02 | N | 250031345 | LIPOSOMAL DOXORUBICIN |
| 250007158 | 250005045 | 1.82 | 56.8 | Adjuvant (A) | 2016-11-11 | 2016-11-17 | RUXOLITINIB | null | null | 250031348 | AZACITIDINE |
| 250007159 | 250005046 | 1.8 | 102 | null | 2017-07-27 | 2017-07-27 | RUXOLITINIB | N | N | 250031349 | RITUXIMAB |
| 250007160 | 250005047 | 1.86 | 51.3 | Palliative (P) | 2017-08-31 | 2017-08-31 | CHOP R - 21 days | N | N | 250031351 | FLUDARABINE + MELPHALAN |
| 250007161 | 250009677 | 0 | 76.9 | Disease modification (D) | 2015-06-24 | 2015-06-24 | Rituximab | N | N | 250031353 | RUXOLITINIB |
| 250007162 | 250005048 | 1.86 | 64.2 | Palliative (P) | 2013-01-08 | 2013-01-08 | Bendamustine+Rituximab (1st Course) | 99 | N | 250031359 | RUXOLITINIB |
| 250007163 | 250005049 | 1.55 | 88.6 | Disease modification (D) | 2017-11-10 | 2017-11-10 | PEG INTERFERON | N | N | 250031360 | RUXOLITINIB |
| 250007164 | 250005050 | 1.65 | 64 | Disease modification (D) | 2017-09-02 | 2017-09-02 | RUXOLITINIB | 2 | N | 250031363 | RITUXIMAB |
| 250007165 | 250005051 | 1.75 | 59 | Curative (C) | 2017-01-08 | 2017-01-08 | Busulfan Oral | 02 | N | 250031365 | CHOP R |
| 250007166 | 250005052 | 1.67 | 0 | Neo-adjuvant (N) | 2014-10-12 | 2014-10-20 | GEMCARBO | N | N | 250031374 | PAZOPANIB |
| 250007167 | 250005053 | 1.56 | 72 | Palliative (P) | 2017-10-22 | 2017-10-22 | DABRAFENIB | N | N | 250031375 | TRIAL |
| 250007168 | 250005054 | 1.64 | 81.9 | Curative (C) | 2016-10-29 | 2016-11-19 | BUSULFAN | N | N | 250031377 | TRIAL |
| 250007169 | 250005055 | null | null | null | 2018-03-09 | 2018-03-09 | RUXOLITINIB | 02 | N | 250031381 | ANAGRELIDE |
| 250007170 | 250005055 | 1.83 | 0 | Curative (C) | 2017-05-29 | 2017-05-29 | THALIDOMIDE | N | N | 250031381 | CHOP R |
| 250007171 | 250005056 | null | null | Palliative (P) | 2015-06-30 | 2015-07-08 | RUXOLITINIB | 02 | N | 250031385 | RUXOLITINIB |
| 250007172 | 250005056 | null | 3 | Curative (C) | 2016-05-08 | 2016-05-08 | RUXOLITINIB | 02 | N | 250031385 | RUXOLITINIB |
| 250007173 | 250005057 | null | 108 | Palliative (P) | 2015-06-11 | 2015-06-15 | RUXOLITINIB | 2 | N | 250031394 | RITUXIMAB |
| 250007174 | 250005057 | 1.67 | null | Disease modification (D) | 2015-03-17 | 2015-03-17 | Trial Unspecified | N | N | 250031394 | RUXOLITINIB |
| 250007175 | 250005057 | 0 | 70.4 | Curative (C) | 2014-08-29 | 2014-09-08 | ANAGRELIDE | N | N | 250031394 | RUXOLITINIB |
| 250007176 | 250005058 | 1.67 | 72.5 | Palliative (P) | 2013-04-12 | 2013-04-12 | RUXOLITINIB | 2 | N | 250031398 | CHOP R |
| 250007177 | 250005059 | null | 84 | null | 2015-11-01 | 2015-11-27 | Enzalutamide | 02 | N | 250031399 | AFLIBERCEPT + FU + IRINOTECAN |
| 250007178 | 250005060 | 1.67 | 75.2 | Disease modification (D) | 2015-03-12 | 2015-03-12 | ANAGRELIDE | N | N | 250031401 | RUXOLITINIB |
| 250007179 | 250005061 | 1.7 | null | Palliative (P) | 2015-01-04 | 2015-01-04 | RUXOLITINIB | 02 | N | 250031403 | RITUXIMAB |
| 250007180 | 250005062 | 1.68 | 73 | Palliative (P) | 2013-06-20 | 2013-06-27 | IMATINIB | 2 | N | 250031404 | RUXOLITINIB |
| 250007181 | 250005063 | null | 0 | Disease modification (D) | 2015-12-13 | 2015-12-13 | Rituximab | 2 | N | 250031408 | CHOP R |
| 250007182 | 250009681 | null | 87.8 | Palliative (P) | null | 2017-08-07 | RUXOLITINIB | N | N | 250031413 | BUSULPHAN |
| 250007183 | 250005064 | 0 | 57.4 | Palliative (P) | null | 2017-05-14 | Trial Unspecified | N | N | 250031416 | BENDAMUSTINE + RITUXIMAB |
| 250007184 | 250005065 | 1.71 | 81.9 | Disease modification (D) | 2017-10-20 | 2017-10-20 | Busulfan Oral | N | N | 250031419 | BUSULPHAN |
| 250007185 | 250005066 | null | null | null | 2015-04-02 | 2015-04-14 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 02 | N | 250031420 | CVD |
| 250007187 | 250005068 | 1.65 | 59 | Palliative (P) | 2015-08-13 | 2015-08-13 | Azacitidine | Y | N | 250031431 | CVP R |
| 250007188 | 250005069 | 1.65 | 73 | Palliative (P) | 2016-08-06 | 2016-08-10 | RUXOLITINIB | N | N | 250031434 | RUXOLITINIB |
| 250007189 | 250005069 | 1.79 | 82 | Palliative (P) | 2015-05-09 | 2015-05-18 | BUSULFAN | 02 | N | 250031434 | RUXOLITINIB |
| 250007190 | 250005069 | 0 | 72 | Curative (C) | 2013-04-17 | 2013-04-17 | CISPLATIN + FLUOROURACIL | N | N | 250031434 | NILOTINIB |
| 250007191 | 250005069 | 0 | 0 | Disease modification (D) | 2013-12-02 | 2013-12-02 | Rituximab | N | N | 250031434 | CVD |
| 250007192 | 250005069 | 0 | null | Curative (C) | 2018-06-08 | 2018-06-09 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN | 2 | N | 250031434 | RUXOLITINIB |
| 250007193 | 250005070 | 0 | 89.3 | Disease modification (D) | 2016-09-15 | 2016-09-15 | RUXOLITINIB | N | N | 250031449 | RITUXIMAB |
| 250007194 | 250005071 | 1.76 | 73 | Curative (C) | 2016-02-07 | 2016-02-09 | BUSULFAN | N | N | 250031451 | RUXOLITINIB |
| 250007195 | 250005071 | 0 | 0 | Disease modification (D) | 2016-07-20 | 2016-07-22 | Alemtuz+Fludara+Melphalan RIC MUD | N | N | 250031451 | BUSULPHAN |
| 250007196 | 250005072 | 0 | 80.8 | Palliative (P) | 2017-05-08 | 2017-06-02 | RUXOLITINIB | N | N | 250031461 | PEG INTERFERON |
| 250007197 | 250005073 | 1.75 | 74.5 | Palliative (P) | 2018-06-04 | 2018-06-04 | Rituximab | N | N | 250031466 | RITUXIMAB |
| 250007198 | 250005073 | 0 | 60 | Neo-adjuvant (N) | 2015-08-03 | 2015-08-05 | RUXOLITINIB | 2 | N | 250031466 | BUSULPHAN |
| 250007199 | 250005073 | null | 67.1 | Palliative (P) | 2013-10-17 | 2013-10-17 | Bendamustine+Rituximab (1st Course) | N | N | 250031466 | RUXOLITINIB |
| 250007200 | 250005074 | null | 63.5 | Palliative (P) | 2013-03-27 | 2013-10-17 | CARBOPLATIN + VINORELBINE | N | N | 250031473 | OXALIPLATIN + MDG |
| 250007201 | 250009685 | null | 104.1 | Disease modification (D) | 2014-08-27 | 2014-08-27 | RUXOLITINIB | 2 | N | 250031482 | PEMBROLIZUMAB |
| 250007202 | 250005075 | 1.65 | 60 | Disease modification (D) | 2014-10-10 | 2014-10-10 | RUXOLITINIB | N | N | 250031485 | RUXOLITINIB |
| 250007203 | 250005076 | null | null | Palliative (P) | 2017-11-26 | 2017-11-26 | ANAGRELIDE | 02 | N | 250031486 | RUXOLITINIB |